Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Total Debt (2019 - 2021)

VYNE Therapeutics (VYNE) has disclosed Total Debt for 3 consecutive years, with $33.4 million as the latest value for Q2 2021.

  • For the quarter ending Q2 2021, Total Debt rose 1.4% year-over-year to $33.4 million, compared with a TTM value of $33.4 million through Jun 2021, up 1.4%, and an annual FY2020 reading of $33.2 million, up 1.37% over the prior year.
  • Total Debt was $33.4 million for Q2 2021 at VYNE Therapeutics, roughly flat from $33.3 million in the prior quarter.
  • Across five years, Total Debt topped out at $52.5 million in Q1 2020 and bottomed at $32.7 million in Q4 2019.
  • Average Total Debt over 3 years is $35.8 million, with a median of $33.2 million recorded in 2020.
  • Peak annual rise in Total Debt hit 1.4% in 2021, while the deepest fall reached 36.57% in 2021.
  • Year by year, Total Debt stood at $32.7 million in 2019, then increased by 1.37% to $33.2 million in 2020, then rose by 0.61% to $33.4 million in 2021.
  • Business Quant data shows Total Debt for VYNE at $33.4 million in Q2 2021, $33.3 million in Q1 2021, and $33.2 million in Q4 2020.